Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia

被引:75
作者
Ramsay, PL
DeMayo, FJ
Hegemier, SE
Wearden, ME
Smith, CV
Welty, SE
机构
[1] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA
[2] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
关键词
D O I
10.1164/ajrccm.164.1.2008022
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects prematurely born infants and appears to evolve in part from early inflammatory responses in the lung. The inflammatory responses have been associated with protein and lipid oxidation in tracheal aspirate fluids. The present study was designed to test the hypothesis that in the first week of life specific oxidations and/ or altered expressions of proteins would be observed in tracheal aspirate fluids in infants who would subsequently develop BPD. We obtained tracheal aspirate fluids on Days of life 1, 3, and 6 from infants born at less than or equal to 29 wk gestation, incubated the fluids with 2,4-dinitrophenylhyrazine (DNPH), separated the proteins electrophoretically, and assessed DNPH reactivity by immunonblots, DNPH reactivity of a protein that was identified as Clara cell secretory protein (CCSP) was observed more consistently in tracheal aspirate fluids from infants who later developed BPD than from infants who did not develop BPD. Tracheal aspirate fluid levels of immunoreactive CCSP were also lower on Day of life 1 in infants who developed BPD than in those who did not develop BPD, Increased CCSP oxidation and decreased immunoreactive CCSP expression in infants who subsequently developed BPD suggest that Clara cell function and CCSP expression may be critical for normal bronchoalveolar fluid homeostasis and that maintaining CCSP expression and function may be useful goals for targeted therapies for inhibition of the development of BPD.
引用
收藏
页码:155 / 161
页数:7
相关论文
共 38 条
[1]  
BONIKOS DS, 1988, BRONCHOPULMONARY DYS, P33
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   Atypical chronic lung disease patterns in neonates [J].
Charafeddine, L ;
D'Angio, CT ;
Phelps, DL .
PEDIATRICS, 1999, 103 (04) :759-765
[4]  
Cotton Robert B., 1996, Pediatric Research, V39, p329A
[5]  
DURAND M, 1990, J PEDIAT, V117, P273
[6]   CHEMISTRY AND BIOCHEMISTRY OF 4-HYDROXYNONENAL, MALONALDEHYDE AND RELATED ALDEHYDES [J].
ESTERBAUER, H ;
SCHAUR, RJ ;
ZOLLNER, H .
FREE RADICAL BIOLOGY AND MEDICINE, 1991, 11 (01) :81-128
[7]   PREPARATION FOR BIRTH INTO AN O-2-RICH ENVIRONMENT - THE ANTIOXIDANT ENZYMES IN THE DEVELOPING RABBIT LUNG [J].
FRANK, L ;
GROSECLOSE, EE .
PEDIATRIC RESEARCH, 1984, 18 (03) :240-244
[8]   PRENATAL DEVELOPMENT OF LUNG ANTIOXIDANT ENZYMES IN 4 SPECIES [J].
FRANK, L ;
SOSENKO, IRS .
JOURNAL OF PEDIATRICS, 1987, 110 (01) :106-110
[9]   HYPOCAPNIA BEFORE SURFACTANT THERAPY APPEARS TO INCREASE BRONCHOPULMONARY DYSPLASIA RISK IN INFANTS WITH RESPIRATORY-DISTRESS SYNDROME [J].
GARLAND, JS ;
BUCK, RK ;
ALLRED, EN ;
LEVITON, A .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1995, 149 (06) :617-622
[10]   A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: A randomized trial [J].
Garland, JS ;
Alex, CP ;
Pauly, TH ;
Whitehead, VL ;
Brand, J ;
Winston, JF ;
Samuels, DP ;
McAuliffe, TL .
PEDIATRICS, 1999, 104 (01) :91-99